Stelis is committed to making biological treatments accessible to patients globally. Our products are targeted against large treatment markets that are currently underserved. Our hybrid operating model combines differentiated bio-similar, novel biologics and authorized manufacture and marketing of in-licensed biologics. With R&D and cGMP manufacturing out of Bangalore, India we aim to bring world-class treatments at affordable costs to patients in Emerging and Developed countries.
source https://www.pharmatutor.org/content/october-2019/walk-in-interview-for-mpharm-msc-bpharm-in-multiple-department-at-stelis-biopharma
No comments:
Post a Comment